SCHEMBL19518053

SCHEMBL19518053

CCCc1nn(C)c2c(=O)nc(-c3cc(C(=O)CN4CCN(CC)CC4)ccc3OCC)[nH]c12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 19/20 0.66
▸ PDE6C P51160 3/20 0.66
▸ HDAC1 Q13547 11/20 0.49
▸ HDAC6 Q9UBN7 10/20 0.49
▸ HDAC2 Q92769 7/20 0.49
▸ PDE3B Q13370 3/20 0.48
▸ PDE3A Q14432 3/20 0.48
▸ HDAC3 O15379 1/20 0.48
▸ NCOR2 Q9Y618 1/20 0.48
▸ PDE2A O00408 1/20 0.46
▸ ABCC4 O15439 1/20 0.46
▸ ABCC5 O15440 1/20 0.46
▸ PDE6D O43924 1/20 0.46
▸ PDE8A O60658 1/20 0.46
▸ PDE9A O76083 1/20 0.46
▸ ABCB11 O95342 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ HTR1A P08908 1/20 0.46
▸ PDE6A P16499 1/20 0.46
▸ PDE6G P18545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18069562 0.94 PDE5A (0.65) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL2032429 0.92 PDE5A (0.78) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL29357402 0.87 PDE5A (0.85) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL2693448 0.87 PDE5A (0.85) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL5964550 0.87 PDE5A (0.70) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL2032052 0.86 PDE5A (0.74) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL30917339 0.85 PDE5A (0.62) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL25013469 0.82 PDE5A (0.85) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL30199753 0.82 PDE5A (0.85) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL19254528 0.82 PDE5A (0.78) PDE5APDE6CHDAC1HDAC6HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190008870-A1 COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER JANSFAT BIOTECHNOLOGY CO LTD (TW) 2019-01-10 — — US disclosed
EP-3241552-A1 COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER Jansfat Biotechnology Co., Ltd. (TW) 2017-11-08 — — EP disclosed
US-20170312286-A1 COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER JANSFAT BIOTECHNOLOGY CO., LTD. (TW) 2017-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170312286-A1 COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER GYS2, PYGL, GYS1 PDE5A 14/4885PDE6C 404/4885HDAC1 1286/4885
US-20190008870-A1 COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER GYS2, PYGL, GYS1 PDE5A 14/4885PDE6C 404/4885HDAC1 1286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback